1
|
Bianchi M, Reichen C, Croset A, Fischer S, Eggenschwiler A, Grübler Y, Marpakwar R, Looser T, Spitzli P, Herzog C, Villemagne D, Schiegg D, Abduli L, Iss C, Neculcea A, Franchini M, Lekishvili T, Ragusa S, Zitt C, Kaufmann Y, Auge A, Hänggi M, Ali W, Frasconi TM, Wullschleger S, Schlegel I, Matzner M, Lüthi U, Schlereth B, Dawson KM, Kirkin V, Ochsenbein AF, Grimm S, Reschke N, Riether C, Steiner D, Leupin N, Goubier A. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. Cancer Immunol Res 2024:745054. [PMID: 38683145 DOI: 10.1158/2326-6066.cir-23-0692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 01/04/2024] [Accepted: 04/19/2024] [Indexed: 05/01/2024]
Abstract
The prognosis of patients with acute myeloid leukemia (AML) is limited, especially for elderly or unfit patients not eligible for hematopoietic stem cell (HSC) transplantation. The disease is driven by leukemic stem cells (LSCs), which are characterized by clonal heterogeneity and resistance to conventional therapy. These cells are therefore believed to be a major cause of progression and relapse. We designed MP0533, a multispecific CD3-engaging DARPin (designed ankyrin repeat protein) that can simultaneously bind to three antigens on AML cells (CD33, CD123, and CD70), aiming to enable avidity-driven T cell-mediated killing of AML cells co-expressing at least two of the antigens. In vitro, MP0533 induced selective T cell-mediated killing of AML cell lines, as well as patient-derived AML blasts and LSCs, expressing two or more target antigens, while sparing healthy HSCs, blood, and endothelial cells. The higher selectivity also resulted in markedly lower levels of cytokine release in normal human blood compared to single antigen-targeting T-cell engagers. In xenograft AML mouse models, MP0533 induced tumor-localized T-cell activation and cytokine release, leading to complete eradication of the tumors while having no systemic adverse effects. These studies show that the multispecific-targeting strategy used with MP0533 holds promise for improved selectivity towards LSCs and efficacy against clonal heterogeneity, potentially bringing a new therapeutic option to this group of patients with high unmet need. MP0533 is currently being evaluated in a dose-escalation phase 1 study in patients with relapsed or refractory AML (NCT05673057).
Collapse
Affiliation(s)
- Matteo Bianchi
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | | | - Amelie Croset
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | | | | | - Yvonne Grübler
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | | | - Thamar Looser
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | | | | | | | - Dieter Schiegg
- Molecular Partners (Switzerland), Schlieren-Zurich, Switzerland
| | - Liridon Abduli
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | - Chloé Iss
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | | | | | | | - Simone Ragusa
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | - Christof Zitt
- Molecular Partners AG, Schlieren-Zurich, Switzerland
| | | | - Alienor Auge
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | - Martin Hänggi
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | - Waleed Ali
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | | | | | - Iris Schlegel
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | - Mirela Matzner
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | | | | | | | | | | | | | - Nina Reschke
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | | | - Daniel Steiner
- Molecular Partners (Switzerland), Schlieren, Switzerland
| | | | - Anne Goubier
- Molecular Partners (Switzerland), Schlieren, Switzerland
| |
Collapse
|
2
|
Bosshart A, Wullschleger S, Behe M, Blanc A, Imobersteg S, Neculcea A, Blunschi J, Abduli L, Schütz S, Wolter J, Reichen C, Croset A, Villa A, Lizak C, Goubier A, Schibli R, Steiner D. Abstract 5037: DARPins as powerful targeting agents for radioligand therapeutics. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-5037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
The development of effective radioligand therapeutics (RLTs) is frequently hampered by the lack of high-quality targeting agents that selectively deliver radioactive payloads to the site of disease while sparing healthy tissues. Antibodies can have high affinity and specificity to tumor targets, but their large size results in limited tumor penetration and long systemic half-life is frequently causing haematological toxicities. Alternatively, targeting agents with low molecular weight such as small molecules and peptides often suffer from limited affinity and specificity to the tumor target, resulting in off-target effects and limited tumor retention. DARPins (Designed Ankyrin Repeat Proteins) developed by Molecular Partners combine small size (15 kDa) and ideal binding properties. Due to their rigid-body target binding mode DARPins combine very high affinity and specificity and unless engineered accordingly, DARPins have very short systemic half-lives. Thanks to a simple and robust architecture, DARPins can be efficiently coupled with radioactive payloads, even at elevated temperatures; and they can tolerate sequence-engineering approaches, which are not compatible with other protein scaffolds. To establish the DARPin platform for RLT, we have used DARPin candidates against different tumor targets. We have previously shown that increasing affinity to the tumor target correlates with elevated tumor uptake and long tumor residence in preclinical mouse models. We now also show that DARPins exhibit a homogeneous and deep tumor penetration in vivo that is highly superior to antibody benchmarks. Globular proteins below 60 kDa in size are typically cleared from the bloodstream via the renal pathway. This generally results in a strong kidney accumulation of small sized, protein-based targeting agents and their coupled residualizing radionuclides, leading to dose-limiting kidney toxicities. To overcome this limitation, we have undertaken an extensive engineering approach of the DARPin scaffold. Our results show that sequence engineering strongly reduces kidney uptake of DARPins without affecting their tumor uptake. This effect was confirmed with independent DARPin candidates suggesting a general applicability of the approach. Combined with other orthogonal strategies, we are able obtain favourable tumor to kidney ratios in preclinical mouse models. These results show that our proprietary optimized DARPin platform offers an attractive solution to the limitations of protein-based targeting agents for RLT applications. Together with the fact that high-affinity DARPins can be generated against a large variety of tumor targets, we conclude that our platform provides a powerful basis for the development of next-generation RLTs. Several DARPin-RLT programs in indications with high unmet medical need are currently in development.
Citation Format: Andreas Bosshart, Stephan Wullschleger, Martin Behe, Alain Blanc, Stefan Imobersteg, Alexandra Neculcea, Jacqueline Blunschi, Liridon Abduli, Sarah Schütz, Julia Wolter, Christian Reichen, Amelie Croset, Alessandra Villa, Christian Lizak, Anne Goubier, Roger Schibli, Daniel Steiner. DARPins as powerful targeting agents for radioligand therapeutics. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5037.
Collapse
Affiliation(s)
| | | | - Martin Behe
- 2Paul Scherrer Institute, Villigen, Switzerland
| | - Alain Blanc
- 2Paul Scherrer Institute, Villigen, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Aguadé-Gorgorió J, McComb S, Eckert C, Guinot A, Marovca B, Mezzatesta C, Jenni S, Abduli L, Schrappe M, Dobay MP, Stanulla M, von Stackelberg A, Cario G, Bourquin JP, Bornhauser BC. TNFR2 is required for RIP1-dependent cell death in human leukemia. Blood Adv 2020; 4:4823-4833. [PMID: 33027529 PMCID: PMC7556136 DOI: 10.1182/bloodadvances.2019000796] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Accepted: 08/19/2020] [Indexed: 12/16/2022] Open
Abstract
Despite major advances in the treatment of patients with acute lymphoblastic leukemia in the last decades, refractory and/or relapsed disease remains a clinical challenge, and relapsed leukemia patients have an exceedingly dismal prognosis. Dysregulation of apoptotic cell death pathways is a leading cause of drug resistance; thus, alternative cell death mechanisms, such as necroptosis, represent an appealing target for the treatment of high-risk malignancies. We and other investigators have shown that activation of receptor interacting protein kinase 1 (RIP1)-dependent apoptosis and necroptosis by second mitochondria derived activator of caspase mimetics (SMs) is an attractive antileukemic strategy not currently exploited by standard chemotherapy. However, the underlying molecular mechanisms that determine sensitivity to SMs have remained elusive. We show that tumor necrosis factor receptor 2 (TNFR2) messenger RNA expression correlates with sensitivity to SMs in primary human leukemia. Functional genetic experiments using clustered regularly interspaced short palindromic repeats/Cas9 demonstrate that TNFR2 and TNFR1, but not the ligand TNF-α, are essential for the response to SMs, revealing a ligand-independent interplay between TNFR1 and TNFR2 in the induction of RIP1-dependent cell death. Further potential TNFR ligands, such as lymphotoxins, were not required for SM sensitivity. Instead, TNFR2 promotes the formation of a RIP1/TNFR1-containing death signaling complex that induces RIP1 phosphorylation and RIP1-dependent apoptosis and necroptosis. Our data reveal an alternative paradigm for TNFR2 function in cell death signaling and provide a rationale to develop strategies for the identification of leukemias with vulnerability to RIP1-dependent cell death for tailored therapeutic interventions.
Collapse
Affiliation(s)
- Júlia Aguadé-Gorgorió
- Department of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zürich, Switzerland
| | - Scott McComb
- Department of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zürich, Switzerland
| | - Cornelia Eckert
- Department of Pediatric Oncology/Hematology, Charité Medical University Berlin, Berlin, Germany
| | - Anna Guinot
- Department of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zürich, Switzerland
| | - Blerim Marovca
- Department of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zürich, Switzerland
| | - Caterina Mezzatesta
- Department of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zürich, Switzerland
| | - Silvia Jenni
- Department of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zürich, Switzerland
| | - Liridon Abduli
- Department of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zürich, Switzerland
| | - Martin Schrappe
- Department of General Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany; and
| | - Maria Pamela Dobay
- Department of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zürich, Switzerland
| | - Martin Stanulla
- Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - Arend von Stackelberg
- Department of Pediatric Oncology/Hematology, Charité Medical University Berlin, Berlin, Germany
| | - Gunnar Cario
- Department of General Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany; and
| | - Jean-Pierre Bourquin
- Department of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zürich, Switzerland
| | - Beat C Bornhauser
- Department of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zürich, Switzerland
| |
Collapse
|
4
|
Mezzatesta C, Abduli L, Guinot A, Eckert C, Schewe D, Zaliova M, Vinti L, Marovca B, Tsai YC, Jenni S, Aguade-Gorgorio J, von Stackelberg A, Schrappe M, Locatelli F, Stanulla M, Cario G, Bourquin JP, Bornhauser BC. Repurposing anthelmintic agents to eradicate resistant leukemia. Blood Cancer J 2020; 10:72. [PMID: 32591499 PMCID: PMC7320149 DOI: 10.1038/s41408-020-0339-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 06/04/2020] [Accepted: 06/08/2020] [Indexed: 12/20/2022] Open
Abstract
Despite rapid progress in genomic profiling in acute lymphoblastic leukemia (ALL), identification of actionable targets and prediction of response to drugs remains challenging. To identify specific vulnerabilities in ALL, we performed a drug screen using primary human ALL samples cultured in a model of the bone marrow microenvironment combined with high content image analysis. Among the 2487 FDA-approved compounds tested, anthelmintic agents of the class of macrocyclic lactones exhibited potent anti-leukemia activity, similar to the already known anti-leukemia agents currently used in induction chemotherapy. Ex vivo validation in 55 primary ALL samples of both precursor B cell and T-ALL including refractory relapse cases confirmed strong anti-leukemia activity with IC50 values in the low micromolar range. Anthelmintic agents increased intracellular chloride levels in primary leukemia cells, inducing mitochondrial outer membrane depolarization and cell death. Supporting the notion that simultaneously targeting cell death machineries at different angles may enhance the cell death response, combination of anthelmintic agents with the BCL-2 antagonist navitoclax or with the chemotherapeutic agent dexamethasone showed synergistic activity in primary ALL. These data reveal anti-leukemia activity of anthelmintic agents and support exploiting drug repurposing strategies to identify so far unrecognized anti-cancer agents with potential to eradicate even refractory leukemia.
Collapse
Affiliation(s)
- Caterina Mezzatesta
- Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
| | - Liridon Abduli
- Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
| | - Anna Guinot
- Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
| | - Cornelia Eckert
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
- German Cancer Consortium (DKTK), Berlin, Germany
| | - Denis Schewe
- Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Marketa Zaliova
- Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Luciana Vinti
- Department of Pediatric Haemato-Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy
| | - Blerim Marovca
- Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
| | - Yi-Chien Tsai
- Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
| | - Silvia Jenni
- Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
| | - Julia Aguade-Gorgorio
- Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
| | - Arend von Stackelberg
- Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
- German Cancer Consortium (DKTK), Berlin, Germany
| | - Martin Schrappe
- Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Franco Locatelli
- Department of Pediatric Haemato-Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy
| | - Martin Stanulla
- Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - Gunnar Cario
- Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Jean-Pierre Bourquin
- Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
| | - Beat C Bornhauser
- Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland.
| |
Collapse
|